Navigation Links
Biomarker could help doctors tailor treatment for rheumatoid arthritis
Date:1/29/2010

Investigators have identified a biomarker that could help doctors select patients with rheumatoid arthritis who will benefit from therapy with drugs such as Enbrel, a tumor necrosis factor (TNF)-antagonist drug. The study, led by researchers at Hospital for Special Surgery in collaboration with rheumatologists at University of Southern California, appears in the February issue of the journal Arthritis & Rheumatism.

"While our study was performed on a relatively small group of patients and will need to be confirmed in a larger cohort, the data are promising and may be clinically significant for the medical management of patients," said Mary K. Crow, M.D., director of Rheumatology Research and co-director of the Mary Kirkland Center for Lupus Research at Hospital for Special Surgery. "Treatment with these drugs is very expensive; the drugs can cost around $16,000 or so per year. If you are going to use them, you would like to know that they are likely to work in your patient." Other well-known TNF-antagonists include Humira and Remicade.

While TNF antagonists have brought relief to thousands of people with rheumatoid arthritis, the drugs are not highly effective in 30 percent to 50 percent of patients. Clinicians thus run the risk of providing a therapy to patients that doesn't work well, is expensive and is potentially toxic. Patients taking TNF antagonists, which have been available for roughly ten years, can run the risk of developing bacterial or fungal infections.

While studies have identified factors associated with poor response to these drugs such as expression of certain genes, none of the factors has as yet provided doctors with a tool that will help select patients who are likely to respond to the drugs or identify those less likely to respond. Investigators at HSS hoped to remedy this and turned their attention to the type I interferon proteins, specifically a type called interferon beta (IFN-beta). Previous studies have revealed that levels of IFN-beta, a protein that can limit cell division, is present in the joint tissue of some patients with rheumatoid arthritis. The researchers wondered if variable levels of this protein could play a role in how patients respond to TNF-antagonist drugs. To test this hypothesis, the investigators set out to determine the relationship between levels of type I interferon activity in the blood prior to beginning therapy and the ability of the drug to control rheumatoid arthritis in patients. They studied the role of IFN-beta, and because they knew that IFN-beta induces interleukin-1 receptor antagonist (IL-1Ra), another protein, they also tested levels of IL-1Ra.

The study involved three cohorts of patients: patients who had rheumatoid arthritis and received a TNF antagonist (n=35), arthritis patients who received no drug (12), and healthy volunteers (n=50). Patients received their care at the Los Angeles County and University of Southern California Medical Center Rheumatology Clinics. Outcomes were evaluated during a window of therapy consisting of more than three months but fewer than nine months, allowing for sufficient time for clinicians to determine clinical response. Doctors used a tool commonly employed to gauge the severity of arthritisthe Disease Activity Score in 28 jointsto deem whether patients had a moderate, good, or no response to the drug.

The investigators found that patients with higher baseline levels of type I IFN were more likely to respond to therapy with TNF antagonists. Patients who had an increased IFN-beta/alpha ratio, meaning they had more IFN-beta, were also more likely to respond to therapy. They also observed significantly higher baseline levels of IL-1Ra in plasma samples from good responders as compared with those from nonresponders or moderate responders.

"We have drawn attention to a potential biomarker that, if our results are supported by additional future studies in other patient populations, might provide a tool to predict who might be a responder to this class of biologic rheumatoid arthritis therapies, the TNF antagonists, and who might be less likely to be a responder," Dr. Crow said. "For those who demonstrate low levels of blood interferon activity, that information might be useful to guide patients to alternative treatments that might be more likely to work for them." This could include the use of other drugs such as Rituximab, which is not a TNF antagonist.


'/>"/>

Contact: Phyllis Fisher
fisherp@hss.edu
212-606-1197
Hospital for Special Surgery
Source:Eurekalert

Related medicine news :

1. First biomarker discovered that predicts prostate cancer outcome
2. Penn School of Medicine receives $2.3 million to study biomarkers of cigarette smoke exposure
3. Study makes progress in zoning in on biomarkers for better colon cancer treatment
4. New Ovarian Cancer Biomarker Research Act Introduced
5. Mayo Clinic study points to a possible biomarker for colon cancer in people 50 and under
6. Singulex Announces Presentation on Monitoring of Cardiac Biomarker to Assess Transient Myocardial Ischemia at the American Heart Association Scientific Sessions
7. Biomarker may be an early predictor of advanced breast cancer
8. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
9. Biomarkers predict risk for invasive breast cancer years before the tumor develops
10. JDRF and Lilly partner to fund research to identify beta cell biomarkers
11. Biomarkers for Alzheimers disease can be trusted in clinical trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 04, 2016 , ... ... surgery can now take advantage of a cosmetic procedure known as Carbon ... that reduces the appearance of age spots, fine lines, uneven coloration, wrinkles, ...
(Date:12/2/2016)... ... , ... Lori G. Cohen and Sara K. Thompson , ... American Conference Institute’s 21st Drug & Medical Device Litigation Conference , taking place ... conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than ... Alabama are expected to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. 9, 2016. ... for area students and operating support to UNCF-member institutions, including Miles College, Oakwood ...
(Date:12/2/2016)... , ... December 02, 2016 , ... The annual time ... Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who are ... or prescription drug plan (Part D) need to make changes during this period order ...
(Date:12/2/2016)... Hills, CA (PRWEB) , ... December 02, 2016 ... ... reconstructive surgeon in Beverly Hills, California, will be included in the 2016 “Guide ... given to exceptional professionals based on the amalgamation of their education, experience, and ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016 The U.S. ... for Jardiance (empagliflozin) to reduce the risk of cardiovascular ... and cardiovascular disease. "Cardiovascular disease is ... 2 diabetes mellitus," said Jean-Marc Guettier , M.D., ... Products in FDA,s Center for Drug Evaluation and Research. ...
(Date:12/2/2016)... , December 2, 2016 bioLytical Laboratories, un líder ... Compañía, el INSTI HIV Self Test , a los miembros de la ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical ...
(Date:12/2/2016)... the ECG Cables And ECG Leadwires Market owing to the ... On the other hand, the Asia-Pacific ... during the forecast period. The market players namely, ... ( Ireland ), Koninklijke Philips N.V. ( ... China ), held major share of the ECG ...
Breaking Medicine Technology: